Abivax (AAVXF) Operating Interest Expenses (2024 - 2026)

Abivax has reported Operating Interest Expenses for 3 years, with the latest figure at $5.6 million in Q1 2026.

• On a quarterly basis, Operating Interest Expenses changed 0.19% year-over-year to $5.6 million in Q1 2026; TTM through Mar 2026 was $53.2 billion, a 250.42% increase from a year earlier, with the FY2025 full-year figure at $53.2 billion, up 250.48% from the prior year.
• Operating Interest Expenses was $5.6 million for Q1 2026 at Abivax, down from $53.2 billion in the prior quarter.
• The five-year high for Operating Interest Expenses was $53.2 billion in Q4 2025, with the low at $3.3 million in Q1 2024.
• Average Operating Interest Expenses over 3 years is $7.6 billion, with a median of $5.7 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Operating Interest Expenses jumped 314.98% in 2025, then retreated 0.19% in 2026.
• Over 3 years, Operating Interest Expenses stood at $15.2 billion in 2024, then soared by 250.56% to $53.2 billion in 2025, then plunged by 99.99% to $5.6 million in 2026.
• The last three Operating Interest Expenses figures came in at $5.6 million (Q1 2026), $53.2 billion (Q4 2025), and $30.5 million (Q3 2025), per Business Quant data.